RSV is a seasonal virus that can cause serious lung infections, especially in young children under 2 years old and adults over 60.
Recently, Health Canada expanded the use of the Arexvy vaccine to include adults aged 50–59 who have certain chronic health conditions that put them at higher risk for severe RSV. These conditions include stable chronic lung diseases like COPD and asthma, heart problems such as heart failure or coronary artery disease, diabetes (both type 1 and type 2), and chronic kidney or liver disease. This update makes the vaccine more widely available to people needing extra protection. We are also aware that people with immune-mediated conditions or those on medications that are considered immunosuppressive are at increased risk of RSV and specialists may also consider them for vaccination before age 60.
There have also been updates about combining Arexvy with other vaccines. It can now be given at the same time as a flu shot, whether it’s a standard dose or a high-dose option. Studies are ongoing to see if it can be safely given alongside other vaccines, like the pneumococcal vaccine (PCV20) and mRNA COVID-19 boosters. Although Arexvy has been studied with the shingles vaccine (Shingrix), this specific combination isn’t officially approved yet.
Remember, it is not necessary to hold or delay most biologic/advanced treatments while receiving non-live vaccines such as Arexvy. We would suggest not administering a new vaccine within a few days of a biologic injection or infusion, so if you feel unwell you can determine which was causing your symptoms.
Joyce Ayad is a pharmacy intern working at Charlton Health. She believes in providing patient-focused care, supported by her previous experience working with specialty drugs, the pharmaceutical industry, and more. Joyce is eager to become a licensed pharmacist this year.